Takeshi Kuwata Selected Research

Adenocarcinoma of Lung

12/2018	Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma.
1/2018	Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
2/2017	Clinicopathological significance of caveolin-1 expression by cancer-associated fibroblasts in lung adenocarcinoma.
1/2017	Fibroblast-led cancer cell invasion is activated by epithelial-mesenchymal transition through platelet-derived growth factor BB secretion of lung adenocarcinoma.
7/2016	The difference in Ezrin-pAkt signaling axis between lepidic and papillary predominant invasive adenocarcinomas of the lung.
1/2016	Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takeshi Kuwata Research Topics

Disease

68	Neoplasms (Cancer) 09/2022 - 01/2003
32	Stomach Neoplasms (Stomach Cancer) 01/2022 - 04/2012
14	Adenocarcinoma 11/2021 - 04/2012
10	Endometrial Neoplasms (Endometrial Cancer) 11/2013 - 01/2003
7	Carcinoma (Carcinomatosis) 10/2016 - 05/2004
6	Adenocarcinoma of Lung 12/2018 - 01/2016
5	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2010
5	Hypoxia (Hypoxemia) 01/2022 - 11/2013
4	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 10/2015
4	Breast Neoplasms (Breast Cancer) 01/2021 - 05/2011
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 08/2021 - 12/2013
3	Disease Progression 01/2021 - 01/2020
3	Residual Neoplasm 01/2021 - 07/2015
2	Necrosis 04/2021 - 01/2019
2	Microsatellite Instability 03/2021 - 01/2021
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 07/2019 - 01/2017
2	Leukemia 01/2019 - 05/2004
2	Lung Neoplasms (Lung Cancer) 05/2018 - 08/2010
2	Carcinogenesis 06/2014 - 08/2012
2	Carcinosarcoma 09/2013 - 06/2009
1	Adenoma (Adenomas) 11/2021
1	Lymphoma (Lymphomas) 10/2021
1	Epstein-Barr Virus Infections 01/2021
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 12/2020
1	Proteinuria 01/2020
1	Exanthema (Rash) 01/2020
1	Cachexia 03/2019

Drug/Important Bio-Agent (IBA)

9	Immune Checkpoint InhibitorsIBA 09/2022 - 01/2020
9	Biomarkers (Surrogate Marker)IBA 03/2021 - 12/2013
8	Biological ProductsIBA 09/2020 - 08/2010
7	human ERBB2 proteinIBA 01/2021 - 01/2014
7	Trastuzumab (Herceptin)FDA Link 01/2021 - 05/2011
6	Proteins (Proteins, Gene)FDA Link 11/2021 - 05/2012
6	Cadherins (E-Cadherin)IBA 01/2021 - 06/2009
6	beta CateninIBA 06/2009 - 01/2003
5	NivolumabIBA 01/2022 - 01/2019
5	CytokinesIBA 01/2021 - 10/2010
5	ErbB Receptors (EGF Receptor)IBA 11/2020 - 01/2015
5	ezrinIBA 01/2018 - 01/2016
4	pembrolizumabIBA 01/2022 - 01/2019
4	CateninsIBA 01/2022 - 12/2010
4	LigandsIBA 01/2021 - 05/2011
4	Carbonic Anhydrase IXIBA 01/2021 - 01/2018
4	ParaffinIBA 12/2020 - 11/2012
4	KalininIBA 07/2019 - 01/2016
3	AntibodiesIBA 01/2022 - 05/2017
3	Phosphotransferases (Kinase)IBA 10/2021 - 01/2019
3	Pharmaceutical PreparationsIBA 06/2021 - 05/2011
3	Formaldehyde (Formol)FDA Link 12/2020 - 01/2015
3	Small Interfering RNA (siRNA)IBA 03/2019 - 11/2012
3	Tumor Suppressor Protein p14ARF (p14ARF)IBA 08/2012 - 11/2006
2	lenvatinibIBA 01/2022 - 01/2020
2	RNA (Ribonucleic Acid)IBA 01/2022 - 10/2015
2	regorafenibIBA 01/2022 - 01/2020
2	VimentinIBA 01/2021 - 09/2013
2	B7-H1 AntigenIBA 01/2021 - 01/2019
2	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 06/2018
2	tyrosine receptor (receptor, tyrosine)IBA 01/2020 - 01/2019
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2019 - 04/2015
2	Monoclonal AntibodiesIBA 01/2019 - 01/2018
2	Epidermal Growth Factor (EGF)IBA 01/2018 - 05/2014
2	Sulfasalazine (Azulfidine)FDA LinkGeneric 11/2017 - 03/2017
2	Becaplermin (PDGF-BB)FDA Link 01/2017 - 08/2010
2	CollagenIBA 01/2017 - 08/2015
2	Growth Factor ReceptorsIBA 01/2017 - 10/2016
2	Transcription Factors (Transcription Factor)IBA 08/2012 - 05/2004
2	Cyclin-Dependent Kinase Inhibitor p16IBA 09/2007 - 11/2006
2	Cyclin D1IBA 11/2006 - 05/2004
1	Antineoplastic Agents (Antineoplastics)IBA 01/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2022
1	Glucose (Dextrose)FDA LinkGeneric 01/2022
1	Prostaglandins AIBA 11/2021
1	DesminIBA 10/2021
1	Calmodulin-Binding Proteins (Caldesmon)IBA 10/2021
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 10/2021
1	Indicators and Reagents (Reagents)IBA 04/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	trastuzumab deruxtecanIBA 01/2021
1	Lapatinib (GW572016)FDA Link 01/2021
1	Ado-Trastuzumab EmtansineIBA 01/2021
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021
1	napabucasinIBA 11/2020
1	Programmed Cell Death 1 ReceptorIBA 11/2020
1	Cetuximab (Erbitux)FDA Link 01/2020
1	Nonesterified Fatty Acids (NEFA)IBA 01/2020
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2020
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2020
1	Interleukin-8 (Interleukin 8)IBA 03/2019
1	amsonic acid (DAS)IBA 01/2019
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2019

Therapy/Procedure

17	Therapeutics 01/2022 - 01/2003
13	Drug Therapy (Chemotherapy) 09/2022 - 09/2012
3	Immunotherapy 01/2022 - 01/2019
3	Neoadjuvant Therapy 01/2021 - 09/2012
2	Gastrectomy 01/2019 - 04/2012
1	Genomic Medicine 11/2021
1	Chemoradiotherapy 08/2021
1	Nephrectomy 04/2021
1	Metastasectomy 05/2019